K-Bio ventures pursue global drug development — notable companies and differentiators in 2021

RudaCure: Targeting diseases with high unmet needs to improve quality of life

RudaCure CEO Yongho Kim spent 15 years conducting basic biomedical research on pain and sensory disorders at university while mentoring the next generation of researchers. Frustrated by the lack of commercialized technologies that could help patients, he founded his own biotech company and is now developing treatments covering the full spectrum of intractable sensory disorders with high unmet needs — from dry eye disease to pain. [Related article: Developing treatments for 'sensory disorders' related to quality of life, from dry eye disease to pain]

Currently, the dry eye disease treatment candidate RCI001 is progressing at the fastest pace, with plans to advance to Phase 1 clinical trials domestically and internationally next year. In addition, the pain treatment RCI002, atopic dermatitis treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related macular degeneration treatment RCI005 are also under development.

메디게이트뉴스